China's National Medical Products Administration (NMPA) has cleared an IND application for a clinical trial of Shanghai Henlius Biotech Inc.'s HLX-60 for the treatment of solid tumors and lymphomas.
Zymeworks Inc. has described new antibody-drug conjugates (ADCs) consisting of a cysteine engineered full-length antibody (IgG type) targeting hepatocyte growth factor receptor (HGFR; MET) or folate receptor α (FOLR1; FR- α) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Suzhou Zelgen Biosciences Co. Ltd. has identified new compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Medshine Discovery Inc. has disclosed new benzylaminoquinazoline derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Impact Therapeutics Inc. has described five-membered heteroaryl-pyrimidine compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Nkgen Biotech Inc. has received IND clearance from the FDA for a phase I study of its cryopreserved off-the-shelf allogeneic blood-derived natural killer (NK) cell therapy SNK-02, to evaluate safety and tolerability in participants with pathologically confirmed solid tumors refractory to standard-of-care therapy.
It’s been a rough year at Macrogenics Inc., but times may be changing. Having terminated a phase II study due to fatalities, dropped 15% of its workforce and closed research and manufacturing sites in the past year, the company has taken the helping hand of Gilead Sciences Inc. The pair have agreed to develop the bispecific MGD-024, which has a CD3 component for minimizing cytokine release syndrome, as an oncology candidate along with two additional bispecific research programs, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes.
To determine if long noncoding RNA (lncRNA) LINC01018 has a tumor-suppressing role in hepatocellular carcinoma (HCC), scientists at the Theodor Bilharz Research Institute and the American University in Cairo developed a therapeutic modality to treat mice with experimental disease.
RSS
